Review



baloxavir acid  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    MedChemExpress baloxavir acid
    Baloxavir Acid, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 60 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/baloxavir acid/product/MedChemExpress
    Average 95 stars, based on 60 article reviews
    baloxavir acid - by Bioz Stars, 2026-02
    95/100 stars

    Images



    Similar Products

    baloxavir acid  (MedChemExpress)
    95
    MedChemExpress baloxavir acid
    Baloxavir Acid, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/baloxavir acid/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    baloxavir acid - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    metabolite pa inhibitor baloxavir acid  (MedChemExpress)
    95
    MedChemExpress metabolite pa inhibitor baloxavir acid
    Effect of <t>baloxavir</t> treatment in mice inoculated with A(H5N1) virus with or without PA-I38M. Female six-week-old BALB/c mice (n = 16/group) were inoculated with 5× MLD 50 of A/California/147/2024 (CA/147, wildtype) (A,C,E,G) or A/California/150/2024 (CA/150, PA-I38M mutation) (B, D, F, H). Immediately after infection (∼2hpi), all inoculated mice we treated twice daily by oral gavage with baloxavir or placebo for 5 days (purple horizontal bar). Survival (A, B) and body weights (C, D) were monitored daily for 14 (CA/147, A and C) or 21 (CA/150, B and D) days (n = 8 mice per treatment dose). Data are mean percentages ± standard deviation (S.D.) of the starting weight. Survival curves were compared by the log-rank Mantel-Cox test. Virus titres in the lungs, brain, spleen and kidney were determined by performing TCID 50 in MDCK-SIAT1 cells at day 3 (E, F) and day 5 (G, H) post-infection (n = 4 mice per treatment condition). Data are means ± S.D.; points represent data from individual mice. The lower limit of detection is indicated by the horizontal dashed line (1.50 log 10 TCID 50 /g). TCID 50 /g, 50% tissue infectious dose per gram of tissue. Two-way ANOVA with Tukey’s multiple comparison test was used for statistical comparison of tissue titres from treated and untreated groups (* p <0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).
    Metabolite Pa Inhibitor Baloxavir Acid, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/metabolite pa inhibitor baloxavir acid/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    metabolite pa inhibitor baloxavir acid - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    baloxavir  (MedChemExpress)
    95
    MedChemExpress baloxavir
    Effect of <t>baloxavir</t> treatment in mice inoculated with A(H5N1) virus with or without PA-I38M. Female six-week-old BALB/c mice (n = 16/group) were inoculated with 5× MLD 50 of A/California/147/2024 (CA/147, wildtype) (A,C,E,G) or A/California/150/2024 (CA/150, PA-I38M mutation) (B, D, F, H). Immediately after infection (∼2hpi), all inoculated mice we treated twice daily by oral gavage with baloxavir or placebo for 5 days (purple horizontal bar). Survival (A, B) and body weights (C, D) were monitored daily for 14 (CA/147, A and C) or 21 (CA/150, B and D) days (n = 8 mice per treatment dose). Data are mean percentages ± standard deviation (S.D.) of the starting weight. Survival curves were compared by the log-rank Mantel-Cox test. Virus titres in the lungs, brain, spleen and kidney were determined by performing TCID 50 in MDCK-SIAT1 cells at day 3 (E, F) and day 5 (G, H) post-infection (n = 4 mice per treatment condition). Data are means ± S.D.; points represent data from individual mice. The lower limit of detection is indicated by the horizontal dashed line (1.50 log 10 TCID 50 /g). TCID 50 /g, 50% tissue infectious dose per gram of tissue. Two-way ANOVA with Tukey’s multiple comparison test was used for statistical comparison of tissue titres from treated and untreated groups (* p <0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).
    Baloxavir, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/baloxavir/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    baloxavir - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    baloxavir treatment  (MedChemExpress)
    95
    MedChemExpress baloxavir treatment
    Effect of <t>baloxavir</t> treatment in mice inoculated with A(H5N1) virus with or without PA-I38M. Female six-week-old BALB/c mice (n = 16/group) were inoculated with 5× MLD 50 of A/California/147/2024 (CA/147, wildtype) (A,C,E,G) or A/California/150/2024 (CA/150, PA-I38M mutation) (B, D, F, H). Immediately after infection (∼2hpi), all inoculated mice we treated twice daily by oral gavage with baloxavir or placebo for 5 days (purple horizontal bar). Survival (A, B) and body weights (C, D) were monitored daily for 14 (CA/147, A and C) or 21 (CA/150, B and D) days (n = 8 mice per treatment dose). Data are mean percentages ± standard deviation (S.D.) of the starting weight. Survival curves were compared by the log-rank Mantel-Cox test. Virus titres in the lungs, brain, spleen and kidney were determined by performing TCID 50 in MDCK-SIAT1 cells at day 3 (E, F) and day 5 (G, H) post-infection (n = 4 mice per treatment condition). Data are means ± S.D.; points represent data from individual mice. The lower limit of detection is indicated by the horizontal dashed line (1.50 log 10 TCID 50 /g). TCID 50 /g, 50% tissue infectious dose per gram of tissue. Two-way ANOVA with Tukey’s multiple comparison test was used for statistical comparison of tissue titres from treated and untreated groups (* p <0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).
    Baloxavir Treatment, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/baloxavir treatment/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    baloxavir treatment - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Effect of baloxavir treatment in mice inoculated with A(H5N1) virus with or without PA-I38M. Female six-week-old BALB/c mice (n = 16/group) were inoculated with 5× MLD 50 of A/California/147/2024 (CA/147, wildtype) (A,C,E,G) or A/California/150/2024 (CA/150, PA-I38M mutation) (B, D, F, H). Immediately after infection (∼2hpi), all inoculated mice we treated twice daily by oral gavage with baloxavir or placebo for 5 days (purple horizontal bar). Survival (A, B) and body weights (C, D) were monitored daily for 14 (CA/147, A and C) or 21 (CA/150, B and D) days (n = 8 mice per treatment dose). Data are mean percentages ± standard deviation (S.D.) of the starting weight. Survival curves were compared by the log-rank Mantel-Cox test. Virus titres in the lungs, brain, spleen and kidney were determined by performing TCID 50 in MDCK-SIAT1 cells at day 3 (E, F) and day 5 (G, H) post-infection (n = 4 mice per treatment condition). Data are means ± S.D.; points represent data from individual mice. The lower limit of detection is indicated by the horizontal dashed line (1.50 log 10 TCID 50 /g). TCID 50 /g, 50% tissue infectious dose per gram of tissue. Two-way ANOVA with Tukey’s multiple comparison test was used for statistical comparison of tissue titres from treated and untreated groups (* p <0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).

    Journal: Emerging Microbes & Infections

    Article Title: Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses from humans in the United States, October 2024 to February 2025

    doi: 10.1080/22221751.2025.2601372

    Figure Lengend Snippet: Effect of baloxavir treatment in mice inoculated with A(H5N1) virus with or without PA-I38M. Female six-week-old BALB/c mice (n = 16/group) were inoculated with 5× MLD 50 of A/California/147/2024 (CA/147, wildtype) (A,C,E,G) or A/California/150/2024 (CA/150, PA-I38M mutation) (B, D, F, H). Immediately after infection (∼2hpi), all inoculated mice we treated twice daily by oral gavage with baloxavir or placebo for 5 days (purple horizontal bar). Survival (A, B) and body weights (C, D) were monitored daily for 14 (CA/147, A and C) or 21 (CA/150, B and D) days (n = 8 mice per treatment dose). Data are mean percentages ± standard deviation (S.D.) of the starting weight. Survival curves were compared by the log-rank Mantel-Cox test. Virus titres in the lungs, brain, spleen and kidney were determined by performing TCID 50 in MDCK-SIAT1 cells at day 3 (E, F) and day 5 (G, H) post-infection (n = 4 mice per treatment condition). Data are means ± S.D.; points represent data from individual mice. The lower limit of detection is indicated by the horizontal dashed line (1.50 log 10 TCID 50 /g). TCID 50 /g, 50% tissue infectious dose per gram of tissue. Two-way ANOVA with Tukey’s multiple comparison test was used for statistical comparison of tissue titres from treated and untreated groups (* p <0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).

    Article Snippet: The active metabolite PA-inhibitor baloxavir acid (MedChemExpress) was dissolved in DMSO.

    Techniques: Virus, Mutagenesis, Infection, Standard Deviation, Comparison